Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.
2.
3.

Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.

Bucko AD, Jarratt M, Stough DB, Kyhl L, Villumsen J, Hall A.

J Dermatolog Treat. 2017 May 25:1-6. doi: 10.1080/09546634.2017.1329506. [Epub ahead of print]

PMID:
28524709
4.

Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.

Jarratt MT, Jones TM, Chang-Lin JE, Tong W, Berk DR, Lin V, Kaoukhov A.

J Drugs Dermatol. 2016 Oct 1;15(10):1250-1259.

PMID:
27741344
5.

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2016 Dec;6(4):639-647. Epub 2016 Aug 30.

6.

Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.

Stein Gold LF, Jarratt MT, Bucko AD, Grekin SK, Berlin JM, Bukhalo M, Weiss JS, Berk DR, Chang-Lin JE, Lin V, Kaoukhov A.

J Drugs Dermatol. 2016 May 1;15(5):553-61.

PMID:
27168264
7.

Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study.

Pariser DM, Eichenfield LF, Bukhalo M, Waterman G, Jarratt M; PDT Study Group.

Br J Dermatol. 2016 Apr;174(4):770-7. doi: 10.1111/bjd.14345. Epub 2016 Feb 28.

PMID:
26663215
8.

Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group.

J Drugs Dermatol. 2014 Nov;13(11):1380-6.

PMID:
25607706
9.

Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis.

Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P.

J Clin Aesthet Dermatol. 2014 Dec;7(12):19-29.

10.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.

J Drugs Dermatol. 2014 Sep;13(9):1124-32.

PMID:
25226015
11.

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group.

Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.

PMID:
25132411
12.

Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.

Fowler J, Tan J, Jackson JM, Meadows K, Jones T, Jarratt M, Leoni M; Brimonidine Phase III Study Group.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):474-81. doi: 10.1111/jdv.12587. Epub 2014 Jul 30.

PMID:
25074756
13.

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

14.

Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind,vehicle-controlled study.

Jarratt M, Jones T, Adelglass J, Bucko A, Pollak R, Roman-Miranda A, Olin JT, Swinyer L.

J Drugs Dermatol. 2014 Jul;13(7):838-46.

PMID:
25007368
15.

Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.

Jackson JM, Fowler J, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M; Brimonidine Phase III Study Group.

J Drugs Dermatol. 2014 Jun;13(6):699-704.

PMID:
24918560
16.

Frequency stabilization of a 369 nm diode laser by nonlinear spectroscopy of Ytterbium ions in a discharge.

Lee MW, Jarratt MC, Marciniak C, Biercuk MJ.

Opt Express. 2014 Mar 24;22(6):7210-21. doi: 10.1364/OE.22.007210.

PMID:
24664069
17.
18.

Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis.

Jarratt M, Siu WJ, Yamakawa E, Kodera N, Pillai R, Smith K.

J Drugs Dermatol. 2013 Sep;12(9):1010-6.

PMID:
24002148
19.
20.

Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study.

Jarratt M, Jones T, Kempers S, Rich P, Morton K, Nakamura N, Tavakkol A.

Cutis. 2013 Apr;91(4):203-10.

PMID:
23763082

Supplemental Content

Loading ...
Support Center